Clinical Therapeutics/New Technology-Oral Agents

Clinical Therapeutics/New Technology-Oral Agents

Open Access
Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study
Diabetes Prevention Program Research Group

Diabetes Care Apr 2019, 42 (4) 601-608; DOI: 10.2337/dc18-1970
Open Access
More Evidence for a Prevention-Related Indication for Metformin: Let the Arguments Resume!
William T. Cefalu, Matthew C. Riddle

Diabetes Care Apr 2019, 42 (4) 499-501; DOI: 10.2337/dci18-0062
Open Access
Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease
Gregory G. Schwartz, Lawrence A. Leiter, Christie M. Ballantyne, Philip J. Barter, Donald M. Black, David Kallend, Fouzia Laghrissi-Thode, Eran Leitersdorf, John J.V. McMurray, Stephen J. Nicholls, Anders G. Olsson, David Preiss, Prediman K. Shah, Jean-Claude Tardif, John Kittelson

Diabetes Care May 2020, 43 (5) 1077-1084; DOI: 10.2337/dc19-2204
You have access
Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight
William I. Sivitz, Lawrence S. Phillips, Deborah J. Wexler, Stephen P. Fortmann, Anne W. Camp, Margaret Tiktin, Magalys Perez, Jacqueline Craig, Priscilla A. Hollander, Andrea Cherrington, Vanita R. Aroda, Meng Hee Tan, Jonathan Krakoff, Neda Rasouli, Nicole M. Butera, Naji Younes, the GRADE Research Group

Diabetes Care May 2020, 43 (5) 940-947; DOI: 10.2337/dc19-1769
You have access
Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults
The RISE Consortium*

Diabetes Aug 2019, 68 (8) 1670-1680; DOI: 10.2337/db19-0299
You have access
Mechanisms of Sodium–Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics
Ele Ferrannini, Ashwin C. Murthy, Yong-ho Lee, Elza Muscelli, Sophie Weiss, Rachel M. Ostroff, Naveed Sattar, Stephen A. Williams, Peter Ganz

Diabetes Care Jun 2020, dc200456; DOI: 10.2337/dc20-0456
You have access
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study
Avivit Cahn, Ofri Mosenzon, Stephen D. Wiviott, Aliza Rozenberg, Ilan Yanuv, Erica L. Goodrich, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Martin Fredriksson, Peter A. Johansson, Anna Maria Langkilde, Marc S. Sabatine, Itamar Raz

Diabetes Care Feb 2020, 43 (2) 468-475; DOI: 10.2337/dc19-1476
Open Access
Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial
Jagdeep S.S. Singh, Ify R. Mordi, Keeran Vickneson, Amir Fathi, Peter T. Donnan, Mohapradeep Mohan, Anna Maria J. Choy, Stephen Gandy, Jacob George, Faisel Khan, Ewan R. Pearson, J. Graeme Houston, Allan D. Struthers, Chim C. Lang

Diabetes Care Jun 2020, 43 (6) 1356-1359; DOI: 10.2337/dc19-2187
Open Access
Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA_1c, in Patients With Type 2 Diabetes
Ali Muhammed Ali, Robert Martinez, Hussein Al-Jobori, John Adams, Curtis Triplitt, Ralph DeFronzo, Eugenio Cersosimo, Muhammad Abdul-Ghani

Diabetes Care Jun 2020, 43 (6) 1234-1241; DOI: 10.2337/dc18-2460
Open Access
Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors
Mariam Alatrach, Nitchakarn Laichuthai, Robert Martinez, Christina Agyin, Ali Muhammed Ali, Hussein Al-Jobori, Olga Lavynenko, John Adams, Curtis Triplitt, Ralph DeFronzo, Eugenio Cersosimo, Muhammad Abdul-Ghani

Diabetes Apr 2020, 69 (4) 681-688; DOI: 10.2337/db19-0770

Main menu

User menu

Search

Clinical Therapeutics/New Technology-Oral Agents

Pages

Navigate

More Information

Other ADA Resources